Relationship between baseline patient-reported health status and patient-centered outcomes after transcatheter aortic valve replacement.

Am Heart JMay 26, 2026 (epub)
Clinical ResearchCardiology

Daijiro Tomii, Jonas Lanz, Dik Heg et al.

✦ AI-curated · Sources linked

In 30 seconds

This post hoc analysis of the multicenter SCOPE I randomized trial examined the relationship between baseline patient-reported health status and outcomes after transcatheter aortic valve replacement (TAVR) in 692 patients with symptomatic severe aortic stenosis. Higher baseline Kansas City Cardiomyopathy Questionnaire overall summary scores (KCCQ-OS) were linked to a greater likelihood of being alive with good health status at 3 years post-TAVR, with an adjusted odds ratio of 5.15 for KCCQ-OS 75-100 compared to 0-25.

Key findings

  • Median baseline KCCQ-OS was 54.9, with 10.7% scoring <25.
  • Patients with KCCQ-OS 50-75 had an adjusted odds ratio of 2.25 for good health status.
  • Patients with KCCQ-OS 75-100 had an adjusted odds ratio of 5.15 for good health status.
  • A linear relationship was observed between baseline KCCQ-OS and all-cause mortality.

Why it matters

Understanding the impact of baseline health status on post-TAVR outcomes can help clinicians better assess patient prognosis and tailor preoperative counseling and management strategies.

Source

Published in Am Heart J. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.